167 related articles for article (PubMed ID: 32907656)
1. Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions.
Carletto A; Zanuzzi M; Sammarco A; Russo P
Int J Technol Assess Health Care; 2020 Dec; 36(6):560-568. PubMed ID: 32907656
[TBL] [Abstract][Full Text] [Related]
2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
3. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
[TBL] [Abstract][Full Text] [Related]
4. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
[TBL] [Abstract][Full Text] [Related]
5. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology.
Inotai A; Pékli M; Jóna G; Nagy O; Remák E; Kaló Z
BMC Health Serv Res; 2012 Sep; 12():332. PubMed ID: 22999574
[TBL] [Abstract][Full Text] [Related]
6. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region.
Augustovski F; Iglesias C; Manca A; Drummond M; Rubinstein A; Martí SG
Pharmacoeconomics; 2009; 27(11):919-29. PubMed ID: 19888792
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review of Health Economic Evaluations Focused on Artificial Intelligence in Healthcare: The Tortoise and the Cheetah.
Voets MM; Veltman J; Slump CH; Siesling S; Koffijberg H
Value Health; 2022 Mar; 25(3):340-349. PubMed ID: 35227444
[TBL] [Abstract][Full Text] [Related]
8. Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service.
Russo P; Zanuzzi M; Carletto A; Sammarco A; Romano F; Manca A
Pharmacoeconomics; 2023 Jan; 41(1):107-117. PubMed ID: 36434415
[TBL] [Abstract][Full Text] [Related]
9. Generalisability in economic evaluation studies in healthcare: a review and case studies.
Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
11. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
Hoomans T; Severens JL; van der Roer N; Delwel GO
Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review of Health Economic Impact Evaluations of Risk Prediction Models: Stop Developing, Start Evaluating.
van Giessen A; Peters J; Wilcher B; Hyde C; Moons C; de Wit A; Koffijberg E
Value Health; 2017 Apr; 20(4):718-726. PubMed ID: 28408017
[TBL] [Abstract][Full Text] [Related]
13. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.
Ultsch B; Damm O; Beutels P; Bilcke J; Brüggenjürgen B; Gerber-Grote A; Greiner W; Hanquet G; Hutubessy R; Jit M; Knol M; von Kries R; Kuhlmann A; Levy-Bruhl D; Perleth M; Postma M; Salo H; Siebert U; Wasem J; Wichmann O
Pharmacoeconomics; 2016 Mar; 34(3):227-44. PubMed ID: 26477039
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
15. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
Linley WG; Hughes DA
Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
[TBL] [Abstract][Full Text] [Related]
16. Quality of clinical and economic evidence in dossier formulary submissions.
Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
[TBL] [Abstract][Full Text] [Related]
17. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
O'Meara S; Riemsma R; Shirran L; Mather L; ter Riet G
Health Technol Assess; 2001; 5(18):1-81. PubMed ID: 11399238
[TBL] [Abstract][Full Text] [Related]
18. How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea.
Bae S; Lee J; Bae EY
Front Pharmacol; 2022; 13():884769. PubMed ID: 35652044
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
